NEO100 Research Shows Impact On Recurrent Grade 4 Astrocytoma
Patients with grade 4 gliomas, particularly those experiencing recurrence, need better treatment options. Researchers are developing NEO100, a clinical-grade version of perillyl alcohol, a natural compound, to be delivered intranasally…
NEO100 Intranasal Delivery Technology Shows Promise for Better Therapeutic Results.
This paper discusses the need for better treatment options for patients suffering from astrocytoma and glioblastoma (GBM), the two most frequently diagnosed primary brain tumors. In addition, secondary brain cancers…
Study Shows NEO400 Has Therapeutic Effect On UV-Induced Skin Damage
A study conducted by NeOnc Technologies Holdings and published in the Wiley Online Research Library examined the effects of NeOnc’s NEO400 formulation for treating skin damage caused by prolonged ultraviolet…
NEO100 Enhances Entry And Therapeutic Activity Of Chimeric Antigen Receptor T Cells
In an article published in the Journal of Neurosurgery website, the study results were posted on Neonc Technologies Holdings’ recent animal study looking at the efficacy of using the NEO100…
Transfemoral Injection of NEO100 Provides Potential for Delivery of Therapeutics to the Brain
In an article published on the Oncotarget.com website, the use of transfemoral injection of NEO100 to provide entry for therapeutics into the brain is explored. The paper provides an overview…
Postsurgical Biopsy Shows Viability of NEO100 Intranasal Delivery
In a recent case trial follow up of a patient with a recurring glioblastoma (GBM) tumor who had been undergoing NEO100 intranasal treatment, a postsurgical biopsy of the tumor showed…
NEO-212 Shows Promise In Treating Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a difficult to treat cancer that starts in the bone marrow and then moves quickly into the blood allowing it to spread to other parts…
NEO100 Enhances Delivery Of Herceptin For Treatment Of Metastatic Breast Cancer In The Brain
The efficacy of human epidermal growth factor receptor 2-targeted therapies, such as humanized monoclonal antibody trastuzumab (Herceptin®, Roche), in patients with breast-to-brain cancer metastasis is hindered by the low permeability…
NEO100 Human Trial In Adult Patients With Recurrent Glioblastoma
A Phase 1 Human Trial of NEO100 was conducted to study the therapeutics’ survivability impact and tolerance capacity. NEO100, which is NeOnc Technology Holdings’ core formulation of highly purified Peryllil Alcohol (POH),…
Understanding The Pharmacokinetic Properties Of NEO 212
This study was conducted to characterize the metabolism and pharmacokinetic properties of NEO 212 in preclinical models. NEO 212, a conjugate of Temozolomide (TMZ) and Perillyl Alcohol (POH), has been…
Study Supporting NEO100’s Ability To Deliver Through The BBB
A new study conducted by NeOnc into the efficacy of its NEO 100 formulation to safely deliver therapeutics to the brain through the Blood-Brain Barrier was concluded in August 2020.…
Improving Therapeutic Efficacy For Brain-Based Cancers Using NEO100
NeOnc Technologies Holdings conducted a study of its NEO100 Perillyl Alcohol (POH) formulation to determine its in vitro Blood-Brain Barrier (BBB) permeability using transepithelial/transendothelial electrical resistance (TEER) and antibody diffusion…
NEO 212 Enhances Temozolomide’s Ability To Increase Radiosensitivity And Cytotoxicity In Glioblastoma Tumors
A new study into the effectiveness of NEO212, a conjugate formulation of Temozolomide (TMZ) and Perillyl Alcohol (POH) designed for intranasal delivery, to enhance the ability of (TMZ) to slow…
NEO100 Enables Noninvasive, Effective Delivery of Therapeutics
A study showed that intranasal delivery with a NEO100-based formulation enables noninvasive, therapeutic delivery to the brain of a pharmaceutical agent that otherwise does not efficiently cross the BBB. One…
Intranasal Delivery Of BZM With NEO 100 Prolonged Survival Of Glioblastoma Tumors In Animals
Many pharmaceutical agents are highly potent but are unable to exert therapeutic activity against disorders of the central nervous system {CNS) because the blood-brain barrier (BBB) impedes their brain entry.…
NEO214 Shown To Be A Mediator Of Cell Death In Patients With TMZ-Resistant GBM
Glioblastoma (GBM) is a highly aggressive primary brain tumor with a poor prognosis. Treatment with temozolomide, the current standard of care for gliomas, usually results in drug resistance and tumor…
POH Shows Ability To Bypass The Blood Brain Barrier For Intranasal Delivery Of Therapeutics
The use of intranasal NEO100 as an agent to treat a neurological disease such as GBM is unique in that it suggests the feasibility of nasal brain delivery via the…
NEO212 Shows Ability To Help Block Pro-Angiogenic And Invasive Characteristics Of GBM
NeOnc Technologies Holdings conducted a study to examine the effects of its NEO212 formulation in helping to block one of the key processes in cancer tumor growth. In tumor cells,…
Further NEO 212 Studies Shows Ability To Slow GBM Cell Invasion at Sub-Cytotoxic Dose
Glioblastoma multiforme (GBM) is a malignant brain tumor characterized by its extensive vascularity, aggressiveness, and invasiveness, where cell migration plays an important role in tumor progression. Its poor prognosis is…
NEO214 Effectively Kills Multiple Myeloma Cells With An Order Of Magnitude Stronger Than Its Individual Components
Despite the introduction of new therapies for multiple myeloma (MM), many patients are still dying from this disease and novel treatments are urgently needed. NeOnc Technologies Holdings, Inc. designed a…
TMZ-POH Shows Positive Effect On Patients With Nasopharyngeal Carcinoma.
In this study, Neonc Technologies Holdings, Inc. showed that the cytotoxicity effects of its patented NEO212 compound Nasopharyngeal carcinoma (NPC) could inhibit NPC cell proliferation, and cause G2/M arrest and…
Initial Study Shows The Cytotoxic Effects Of Intranasal Delivered POH
On one of its first studies looking at the effects of intranasal-delivered POH as a therapeutic for cancer, NeOnc Technologies Holdings, Inc. demonstrated that its NEO100 formulation had a marked…
NEO100 Research Shows Impact On Recurrent Grade 4 Astrocytoma
Patients with grade 4 gliomas, particularly those experiencing recurrence, need better treatment options. Researchers are developing NEO100, a clinical-grade version of perillyl alcohol, a natural compound, to be delivered intranasally…
NEO100 Intranasal Delivery Technology Shows Promise for Better Therapeutic Results.
This paper discusses the need for better treatment options for patients suffering from astrocytoma and glioblastoma (GBM), the two most frequently diagnosed primary brain tumors. In addition, secondary brain cancers…
NEO100 Enhances Entry And Therapeutic Activity Of Chimeric Antigen Receptor T Cells
In an article published in the Journal of Neurosurgery website, the study results were posted on Neonc Technologies Holdings’ recent animal study looking at the efficacy of using the NEO100…
Transfemoral Injection of NEO100 Provides Potential for Delivery of Therapeutics to the Brain
In an article published on the Oncotarget.com website, the use of transfemoral injection of NEO100 to provide entry for therapeutics into the brain is explored. The paper provides an overview…
Postsurgical Biopsy Shows Viability of NEO100 Intranasal Delivery
In a recent case trial follow up of a patient with a recurring glioblastoma (GBM) tumor who had been undergoing NEO100 intranasal treatment, a postsurgical biopsy of the tumor showed…
NEO100 Enhances Delivery Of Herceptin For Treatment Of Metastatic Breast Cancer In The Brain
The efficacy of human epidermal growth factor receptor 2-targeted therapies, such as humanized monoclonal antibody trastuzumab (Herceptin®, Roche), in patients with breast-to-brain cancer metastasis is hindered by the low permeability…
NEO100 Human Trial In Adult Patients With Recurrent Glioblastoma
A Phase 1 Human Trial of NEO100 was conducted to study the therapeutics’ survivability impact and tolerance capacity. NEO100, which is NeOnc Technology Holdings’ core formulation of highly purified Peryllil Alcohol (POH),…
Study Supporting NEO100’s Ability To Deliver Through The BBB
A new study conducted by NeOnc into the efficacy of its NEO 100 formulation to safely deliver therapeutics to the brain through the Blood-Brain Barrier was concluded in August 2020.…
Improving Therapeutic Efficacy For Brain-Based Cancers Using NEO100
NeOnc Technologies Holdings conducted a study of its NEO100 Perillyl Alcohol (POH) formulation to determine its in vitro Blood-Brain Barrier (BBB) permeability using transepithelial/transendothelial electrical resistance (TEER) and antibody diffusion…
NEO100 Enables Noninvasive, Effective Delivery of Therapeutics
A study showed that intranasal delivery with a NEO100-based formulation enables noninvasive, therapeutic delivery to the brain of a pharmaceutical agent that otherwise does not efficiently cross the BBB. One…
Intranasal Delivery Of BZM With NEO 100 Prolonged Survival Of Glioblastoma Tumors In Animals
Many pharmaceutical agents are highly potent but are unable to exert therapeutic activity against disorders of the central nervous system {CNS) because the blood-brain barrier (BBB) impedes their brain entry.…
POH Shows Ability To Bypass The Blood Brain Barrier For Intranasal Delivery Of Therapeutics
The use of intranasal NEO100 as an agent to treat a neurological disease such as GBM is unique in that it suggests the feasibility of nasal brain delivery via the…
Initial Study Shows The Cytotoxic Effects Of Intranasal Delivered POH
On one of its first studies looking at the effects of intranasal-delivered POH as a therapeutic for cancer, NeOnc Technologies Holdings, Inc. demonstrated that its NEO100 formulation had a marked…
NEO-212 Shows Promise In Treating Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a difficult to treat cancer that starts in the bone marrow and then moves quickly into the blood allowing it to spread to other parts…
Understanding The Pharmacokinetic Properties Of NEO 212
This study was conducted to characterize the metabolism and pharmacokinetic properties of NEO 212 in preclinical models. NEO 212, a conjugate of Temozolomide (TMZ) and Perillyl Alcohol (POH), has been…
NEO 212 Enhances Temozolomide’s Ability To Increase Radiosensitivity And Cytotoxicity In Glioblastoma Tumors
A new study into the effectiveness of NEO212, a conjugate formulation of Temozolomide (TMZ) and Perillyl Alcohol (POH) designed for intranasal delivery, to enhance the ability of (TMZ) to slow…
NEO212 Shows Ability To Help Block Pro-Angiogenic And Invasive Characteristics Of GBM
NeOnc Technologies Holdings conducted a study to examine the effects of its NEO212 formulation in helping to block one of the key processes in cancer tumor growth. In tumor cells,…
Further NEO 212 Studies Shows Ability To Slow GBM Cell Invasion at Sub-Cytotoxic Dose
Glioblastoma multiforme (GBM) is a malignant brain tumor characterized by its extensive vascularity, aggressiveness, and invasiveness, where cell migration plays an important role in tumor progression. Its poor prognosis is…
TMZ-POH Shows Positive Effect On Patients With Nasopharyngeal Carcinoma.
In this study, Neonc Technologies Holdings, Inc. showed that the cytotoxicity effects of its patented NEO212 compound Nasopharyngeal carcinoma (NPC) could inhibit NPC cell proliferation, and cause G2/M arrest and…
NEO214 Shown To Be A Mediator Of Cell Death In Patients With TMZ-Resistant GBM
Glioblastoma (GBM) is a highly aggressive primary brain tumor with a poor prognosis. Treatment with temozolomide, the current standard of care for gliomas, usually results in drug resistance and tumor…
NEO214 Effectively Kills Multiple Myeloma Cells With An Order Of Magnitude Stronger Than Its Individual Components
Despite the introduction of new therapies for multiple myeloma (MM), many patients are still dying from this disease and novel treatments are urgently needed. NeOnc Technologies Holdings, Inc. designed a…
Study Shows NEO400 Has Therapeutic Effect On UV-Induced Skin Damage
A study conducted by NeOnc Technologies Holdings and published in the Wiley Online Research Library examined the effects of NeOnc’s NEO400 formulation for treating skin damage caused by prolonged ultraviolet…